BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Acitretin and teratogenicity: Extension of the period of pregnancy prevention to 3 years after end of treatment

Active substance: Acitretin

The BfArM issues information on the result of the European PSUR worksharing procedure for the active substance acitretin. It was determined that the current 2-year period of pregnancy prevention after end of treatment is not sufficient and must therefore be extended to 3 years.

To the risk information - full text (available in German only)

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK